Rontalizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Rontalizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetIFN-α
Clinical data
ATC code
  • none
Identifiers
CAS Number
  • 948570-30-7 ☒N
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6486H9990N1722O2026S44
Molar mass145917.93 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Rontalizumab is a humanized monoclonal antibody[1] being developed by Genentech.[2] As of November 2009, it is being investigated in a clinical trial for the treatment of systemic lupus erythematosus.[3][4]

References[edit]

  1. ^ WHO Drug Information
  2. ^ Genentech: Rontalizumab (rhuMAb IFN alpha)
  3. ^ Clinical trial number NCT00962832 for "A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (ROSE)" at ClinicalTrials.gov
  4. ^ Misra DP, Negi VS (March 2017). "Interferon targeted therapies in systemic lupus erythematosus". Mediterranean Journal of Rheumatology. 28 (1): 13–19. doi:10.31138/mjr.28.1.13. PMC 7045923. PMID 32185249.